| Patient characteristics | Post-LTx nonsmokers | Post-LTx smokers | p-value |
| Patients n | 292 | 39 | |
| Type of LTx | 0.17 | ||
| SSLTx | 232 (79) | 28 (72) | 0.27 |
| SLTx | 43 (15) | 10 (26) | 0.08 |
| Heart–lung | 17 (6) | 1 (2) | 0.40 |
| Underlying disease | <0.0001* | ||
| Emphysema | 131 (45) | 36 (91) | <0.0001* |
| Cystic fibrosis | 66 (22) | 1 (3) | 0.0034* |
| ILD | 44 (15) | 0 (0) | 0.0092* |
| PAH | 28 (10) | 1 (3) | 0.15 |
| Other | 23 (8) | 1 (3) | 0.23 |
| Age years | 52 (37–58) | 54 (49–57) | 0.062 |
| Males | 144 (49) | 20 (51) | 0.82 |
| Smokers before LTx | 178 (61) | 39 (100) | <0.0001* |
| Second-hand smoking | 92 (28) | 33 (75) | <0.0001* |
| Oncological events | 26 (9) | 10 (26) | 0.0043* |
| Solid tissue cancer | 15 (5) | 8 (20) | 0.0024* |
| Time to diagnose days | 1460 (432–2023) | 1900 (575–2555) | 0.16 |
| Lung cancer | 6 (2) | 4 (10) | 0.021* |
| Time to diagnose days | 2048 (1185–2516) | 2448 (1383–2851) | 0.61 |
Data are presented as n (%) or median (interquartile range), unless otherwise stated. LTx: lung transplantation; SSLTx: sequential single lung transplantation; SLTx: single lung transplantation; ILD: interstitial lung disease; PAH: pulmonary arterial hypertension. *: p<0.05 was considered significant.